Drugs / Bupivacaine Liposome Injection
Bupivacaine Liposome Injection
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03574376 Comparator | Aug 2018 → Aug 2020 | — | Chadrick Evans | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bupivacaine Liposome Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03574376 ↗ |
| Modality | Other / unclassified | “Liposome bupivacaine (Exparel) is a multivesicular liposomal formulation of bupivacaine” PMID 26204387 ↗ Sep 2015 |
| Route | Other | “the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected” NCT03574376 ↗ |